Clinical Trials on Locally Advanced Malignant Skin Neoplasm in Japan
Total 675 results
-
Daiichi Sankyo Co., Ltd.Completed
-
Daiichi Sankyo Co., Ltd.Terminated
-
Puma Biotechnology, Inc.Completed
-
Puma Biotechnology, Inc.CompletedAdvanced Malignant Solid TumorsJapan
-
Astellas Pharma IncCompletedLocally Advanced (Unresectable) or Metastatic Solid Tumor MalignanciesJapan
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan
-
Puma Biotechnology, Inc.CompletedAdvanced Malignant Solid TumorsJapan
-
Astellas Pharma Global Development, Inc.Merck Sharp & Dohme LLC; Seagen Inc.RecruitingLocally Advanced or Metastatic Malignant Solid TumorsUnited States, Japan, Canada
-
AstraZenecaCompletedAdvanced Solid Tumor | Advanced Solid MalignancyJapan
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of, China, Japan
-
PfizerCompletedNeoplasm, MalignantJapan
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Malignant Solid TumorUnited States, Japan
-
SanofiCompletedNeoplasm MalignantJapan
-
University of Texas Southwestern Medical CenterWithdrawnLocally Advanced Pancreatic AdenocarcinomaUnited States, Japan
-
AstraZenecaTerminatedInoperable Locally Advanced or Metastatic Biliary Tract CancerJapan
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
SanofiCompletedNeoplasm MalignantJapan
-
AstraZenecaRecruitingLocally Advanced (Inoperable) or Metastatic Breast CancerSpain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
-
Daiichi Sankyo Co., Ltd.AstraZenecaCompletedMalignant Neoplasm of BreastJapan
-
SanofiCompleted
-
National Cancer Center Hospital EastJapan Agency for Medical Research and DevelopmentRecruitingLocally Advanced Rectal CancerJapan
-
National Cancer Center, JapanOno Pharmaceutical Co. Ltd; Fiverings Co., Ltd.Active, not recruitingLocally Advanced Esophageal Squamous Cell CarcinomaJapan
-
SanofiCompletedNeoplasm MalignantKorea, Republic of, Japan
-
AstraZenecaCompletedAdvanced Solid Malignancies | Malignant LymphomaUnited Kingdom, Japan
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Shoichi Fujii, MD, PhDUnknownMalignant Neoplasm of Transverse Colon | Malignant Neoplasm of Descending ColonJapan
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
-
AstraZenecaActive, not recruitingLocally Advanced (Inoperable) or Metastatic Breast CancerUnited States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
PfizerTerminatedLocally Advanced or Metastatic Solid Tumors | Genes, BRCA 1United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
-
GenmabBioNTech SERecruitingMalignant Solid TumorJapan
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerJapan
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdCompletedMalignant TumorsJapan
-
AstraZenecaCompletedPart A and B: Advanced Solid Malignancies | Part C: Malignant MesotheliomaJapan
-
Ono Pharmaceutical Co. LtdCompletedMalignant Solid TumorJapan
-
AstraZenecaCompleted
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
SanofiCompleted
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Bristol-Myers SquibbCompletedLocally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal JunctionFrance, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
-
AstraZenecaActive, not recruitingAdvanced Solid MalignanciesJapan
-
Novartis PharmaceuticalsCompleted
-
Eli Lilly and CompanyParexelCompleted
-
AstraZenecaCompleted